UBS Group Cuts Henry Schein (NASDAQ:HSIC) Price Target to $80.00

Henry Schein (NASDAQ:HSIC) had its price objective lowered by UBS Group from $83.00 to $80.00 in a research note released on Wednesday morning,Benzinga reports. The firm currently has a neutral rating on the stock.

Other equities analysts have also recently issued reports about the company. Jefferies Financial Group raised their target price on Henry Schein from $77.00 to $80.00 and gave the company a “hold” rating in a report on Thursday, January 23rd. Mizuho assumed coverage on Henry Schein in a report on Wednesday, December 4th. They set a “neutral” rating and a $75.00 target price for the company. Bank of America raised Henry Schein from an “underperform” rating to a “buy” rating and increased their price target for the company from $69.00 to $84.00 in a research report on Monday, January 6th. Wells Fargo & Company assumed coverage on Henry Schein in a research report on Friday, February 14th. They issued an “equal weight” rating and a $80.00 price target on the stock. Finally, Barrington Research reaffirmed an “outperform” rating and issued a $90.00 price target on shares of Henry Schein in a research report on Wednesday. Six analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $81.10.

Henry Schein Stock Performance

Shares of Henry Schein stock opened at $72.17 on Wednesday. The business has a 50-day moving average of $74.35 and a 200 day moving average of $72.42. Henry Schein has a 12 month low of $63.67 and a 12 month high of $82.49. The stock has a market capitalization of $9.00 billion, a price-to-earnings ratio of 29.70, a price-to-earnings-growth ratio of 2.13 and a beta of 0.91. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.04). Henry Schein had a net margin of 2.51% and a return on equity of 12.90%. The firm had revenue of $3.19 billion for the quarter, compared to analysts’ expectations of $3.25 billion. During the same quarter last year, the business earned $0.66 earnings per share. The business’s revenue was up 5.8% compared to the same quarter last year. As a group, sell-side analysts forecast that Henry Schein will post 4.74 earnings per share for the current year.

Institutional Investors Weigh In On Henry Schein

Several hedge funds and other institutional investors have recently made changes to their positions in HSIC. Palestra Capital Management LLC acquired a new stake in shares of Henry Schein during the 4th quarter worth about $182,988,000. Lyrical Asset Management LP purchased a new position in Henry Schein during the 4th quarter worth approximately $126,655,000. Norges Bank purchased a new position in Henry Schein during the 4th quarter worth approximately $103,301,000. Steadfast Capital Management LP grew its stake in Henry Schein by 254.2% during the 4th quarter. Steadfast Capital Management LP now owns 1,637,808 shares of the company’s stock worth $113,336,000 after buying an additional 1,175,408 shares during the last quarter. Finally, ING Groep NV purchased a new position in Henry Schein during the 3rd quarter worth approximately $63,226,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.